1. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective
- Author
-
M Shikano, M Sato, S Kijima, Y Ochiai, N Nagai, Y Nomura, and Y Ando
- Subjects
Engineering ,Operations research ,business.industry ,030226 pharmacology & pharmacy ,Modeling and simulation ,03 medical and health sciences ,Engineering management ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Modeling and Simulation ,Drug approval ,Pharmacology (medical) ,Electronic data ,business - Abstract
In Japan in October 2016, the Pharmaceuticals and Medical Devices Agency (PMDA) began to receive electronic data in new drug applications (NDAs). These electronic data are useful to conduct regulatory assessment of sponsors' submissions and contribute to the PMDA's research. In this article, we summarize the number of submissions of quantitative modeling and simulation (M&S) documents in NDAs in Japan, and we describe our current thinking and activities about quantitative M&S in PMDA.
- Published
- 2017